CDL Kasauli clears over 21 lakh Gennova Biopharma mRNA COVID vaccine doses: Sources
Gennova's mRNA vaccine is an Omicron-specific vaccine and has already tweaked its mRNA platform that will target Omicron.
New Delhi: The Central Drugs Laboratory (CDL), Kasauli has cleared more than 21 lakh mRNA COVID-19 vaccine doses for stockpiling, the sources told ANI.
India has started stockpiling its first mRNA Covid 19 vaccine. This vaccine is manufactured by Pune-based Gennova Biopharmaceuticals Ltd.
The CDL Kasauli under the Health Ministry is responsible for checking the safety and efficacy of the vaccine, the sources said.
Gennova's mRNA vaccine is an Omicron-specific vaccine and has already tweaked its mRNA platform that will target Omicron.
ANI went further and generated some more queries to the company about the latest updates on data submitted to CDSCO but the company refused to answer.
Read also: CDSCO allows import of drugs with residual shelf life less than 60 percent till October 31, 2021
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.